Senators question Allergan CEO on tribe patent deal
Por um escritor misterioso
Descrição
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks
Page 67 – Business North Carolina
Judge asks if Allergan's patent deal with Mohawk tribe is a 'sham
Patent transfer to Mohawk tribe intended to stop generic drugs
Tangible IP's Latest IP Market Update
Prescription Drug Costs
Allergan deal with Mohawk tribe casts patent shadow
Allergan CEO Defends Mohawk Tribe Restasis Patent Deal
Patent Move Was 'Nuts,' Regeneron CEO Tells Allergan Chief - Bloomberg
